“We started this company looking at the current genomics field and evaluating the gap we’re trying to fill,” Molly He, CEO and co-founder of Element Biosciences, explains to Bloomberg Intelligence. Dr. He joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the intricacies of building a new gene-sequencing instrument from scratch, the challenges of getting customers to adopt technology from new entrants and why the extension of the AVITI system beyond DNA into protein and cellular analysis is so important.

<p>“We started this company looking at the current genomics field and evaluating the gap we’re trying to fill,” Molly He, CEO and co-founder of Element Biosciences, explains to Bloomberg Intelligence. Dr. He joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the intricacies of building a new gene-sequencing instrument from scratch, the challenges of getting customers to adopt technology from new entrants and why the extension of the AVITI system beyond DNA into protein and cellular analysis is so important.</p>

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Health Care by Bloomberg Intelligence

Element Biosciences Looks to Go Beyond Just Sequencing with AVITI

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/23699bc9-cd54-4800-8ae7-b116014c1ab5/transcript